Losartan Potassium Tablet, Film Coated
Product Images NDC 82009-042

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 82009-042). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losapotatab1 (D1af6550 E4ba 4015 8b4a 11caab0b95f6 01)

Chemical structure of Losartan Potassium, depicting its molecular components including a tetrazole ring, biphenyl group, and potassium ion.*

FDA Label Image

Losapotatab2 (D1af6550 E4ba 4015 8b4a 11caab0b95f6 02)

A line graph comparing the percentage of patients with a primary endpoint over 66 months for Atenolol (dashed line) and Losartan Potassium (solid line). The x-axis represents study months and the y-axis shows the percentage of patients. The graph notes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Losapotatab3 (D1af6550 E4ba 4015 8b4a 11caab0b95f6 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Losartan Potassium and Atenolol. The vertical axis represents the percentage of patients, and the horizontal axis shows study duration in months. Losartan Potassium shows a lower stroke rate compared to Atenolol, with a noted adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Losapotatab (D1af6550 E4ba 4015 8b4a 11caab0b95f6 04)

A forest plot comparing the hazard ratios of primary composite events and stroke (fatal/non-fatal) between Losartan-K and Atenolol across various patient subgroups including age, gender, race, ISH status, diabetes, and history of cardiovascular disease. The plot displays event rates, confidence intervals, and markers indicating favor towards Losartan-K or Atenolol.*

FDA Label Image

Losapotatab5 (D1af6550 E4ba 4015 8b4a 11caab0b95f6 05)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium Tablet and placebo groups. The x-axis represents time in months, and the y-axis shows the percentage of patients with events, with the Losartan Potassium group's line below the placebo group's line, indicating a 16.1% risk reduction with a p-value of 0.022.*

FDA Label Image

Losapotataba (D1af6550 E4ba 4015 8b4a 11caab0b95f6 06)

Label for Losartan Potassium Tablets, USP 25 mg by Quallent Pharmaceuticals Health LLC, presented in a 1,000 count bottle. The label includes dosage strength, NDC number 82009-042-10, storage instructions, and manufacturer details including Zydus Lifesciences Ltd., Ahmedabad, India. The label highlights the prescription-only status and advises to keep out of reach of children.*

FDA Label Image

Losapotatabb (D1af6550 E4ba 4015 8b4a 11caab0b95f6 07)

Label for Losartan Potassium Tablets USP 50 mg, film-coated oral tablets, provided by Quallent Pharmaceuticals Health LLC. The label shows an NDC 82009-043-10 for a package quantity of 1,000 tablets. It includes storage instructions, manufacturer details, and usage notes typical for prescription drug packaging.*

FDA Label Image

Losapotatabc (D1af6550 E4ba 4015 8b4a 11caab0b95f6 08)

The label for Losartan Potassium Tablets, USP, 100 mg, oral film-coated tablets, provided in a 1,000 count package. The label includes dosage strength, storage instructions, manufacturer (Zydus Lifesciences Ltd., India), and labeler (Quallent Pharmaceuticals Health LLC). The label also includes barcode, NDC 82009-044-10, and safety warnings to keep out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.